Tame Mihoko A, Manjón Anna G, Belokhvostova Daria, Raaijmakers Jonne A, Medema René H
Division of Cell Biology and Cancer Genomics Center, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Oncotarget. 2017 May 10;8(42):71536-71547. doi: 10.18632/oncotarget.17740. eCollection 2017 Sep 22.
Microtubules are cellular targets for a variety of anticancer therapies because of their critical function in mitosis. Taxol belongs to a class of microtubule targeting agents that suppresses microtubule dynamics and interferes with the functioning of the mitotic spindle, thereby effectively blocking cell cycle progression of rapidly proliferating tumor cells. Despite its antitumor activity, drug resistance remains a common obstacle in improving its overall clinical efficacy. Previous studies have shown that the expression of a specific β-tubulin isotype, βIII-tubulin/TUBB3, is dysregulated in drug-refractory tumors. However, whether enhanced TUBB3 expression is directly involved in promoting taxol resistance remains a subject of debate. Here, we have used several approaches to assess the functional relation of TUBB3 overexpression and taxol resistance. First, we generated a number of taxol-resistant cell lines, to find that TUBB3 expression was elevated in a resistant cell line (RPE-20) derived from untransformed retinal pigment epithelial (RPE) cells, but the abundance of TUBB3 remained unchanged in four other cell lines after taxol treatment. However, although RPE-20 cells displayed enhanced TUBB3 levels, we find that simultaneous up-regulation of the P-glycoprotein (P-gP) drug-efflux pump is responsible for the resistance to taxol. Indeed, we could show that TUBB3 levels were dynamically regulated upon taxol exposure and withdrawal, unrelated to the resistance phenotype. Next, we generated cell lines in which we could induce robust overexpression of TUBB3 from its endogenous locus employing the CRISPRa system. We demonstrate that solely enhancing TUBB3 expression results in a very minor decrease in the sensitivity to taxol. This was further substantiated by selective depletion of TUBB3 in a series of breast cancer cell lines expressing high levels of TUBB3. We find that TUBB3 depletion had a minimal effect on the sensitivity to taxol in one of these cell lines, but had no effect in all of the others. Based on these findings we propose that TUBB3 overexpression can only marginally affect the sensitivity to taxol in cultured cell lines.
微管是多种抗癌疗法的细胞靶点,因为它们在有丝分裂中具有关键功能。紫杉醇属于一类微管靶向剂,可抑制微管动力学并干扰有丝分裂纺锤体的功能,从而有效阻断快速增殖的肿瘤细胞的细胞周期进程。尽管其具有抗肿瘤活性,但耐药性仍然是提高其总体临床疗效的常见障碍。先前的研究表明,一种特定的β-微管蛋白亚型βIII-微管蛋白/TUBB3在耐药肿瘤中表达失调。然而,TUBB3表达增强是否直接参与促进紫杉醇耐药性仍存在争议。在这里,我们使用了几种方法来评估TUBB3过表达与紫杉醇耐药性之间的功能关系。首先,我们生成了一些紫杉醇耐药细胞系,发现来自未转化的视网膜色素上皮(RPE)细胞的耐药细胞系(RPE-20)中TUBB3表达升高,但在另外四个细胞系中,紫杉醇处理后TUBB3的丰度保持不变。然而,尽管RPE-20细胞显示TUBB3水平升高,但我们发现P-糖蛋白(P-gP)药物外排泵的同时上调是对紫杉醇耐药的原因。事实上,我们可以证明,紫杉醇暴露和撤药后TUBB3水平会动态调节,与耐药表型无关。接下来,我们生成了细胞系,在其中我们可以使用CRISPRa系统从其内源性位点诱导TUBB3的强烈过表达。我们证明,仅增强TUBB3表达只会导致对紫杉醇的敏感性略有降低。在一系列表达高水平TUBB3的乳腺癌细胞系中选择性耗尽TUBB3进一步证实了这一点。我们发现,TUBB3的耗尽对其中一个细胞系对紫杉醇的敏感性影响最小,但对其他所有细胞系均无影响。基于这些发现,我们提出TUBB3过表达在培养的细胞系中仅能轻微影响对紫杉醇的敏感性。